ARVN - CIK 0001655759
ARVINAS, INC. trades as ARVN. In its fiscal 2025 annual report the company posted revenue of $262.60M, down 0.3% from the prior year and net income of -$81.00M. This page tracks ARVINAS, INC. through 575 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 8 fiscal years ARVINAS, INC.'s revenue grew from $7.58M to $262.60M, a compound annual growth rate of 55.8%. Net profit margin expanded from -317.3% to -30.8% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-20 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| Major company event | 8-K | 2026-05-12 |
The largest companies sharing ARVINAS, INC.'s SEC industry classification (pharmaceutical preparations).
ARVINAS, INC. reported revenue of $262.60M for fiscal year 2025, a decrease of 0.3% year over year.
In its latest fiscal year ARVINAS, INC. reported a net loss of $81.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.